PMID- 38533514
OWN - NLM
STAT- MEDLINE
DCOM- 20240328
LR  - 20240402
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 15
DP  - 2024
TI  - Single-cell transcriptome sequencing provides insight into multiple chemotherapy 
      resistance in a patient with refractory DLBCL: a case report.
PG  - 1303310
LID - 10.3389/fimmu.2024.1303310 [doi]
LID - 1303310
AB  - Relapsed and refractory diffuse large B-cell lymphoma (DLBCL) is associated with 
      poor prognosis. As such, a comprehensive analysis of intratumoral components, 
      intratumoral heterogeneity, and the immune microenvironment is essential to 
      elucidate the mechanisms driving the progression of DLBCL and to develop new 
      therapeutics. Here, we used single-cell transcriptome sequencing and conventional 
      bulk next-generation sequencing (NGS) to understand the composite tumor landscape 
      of a single patient who had experienced multiple tumor recurrences following 
      several chemotherapy treatments. NGS revealed several key somatic mutations that 
      are known to contribute to drug resistance. Based on gene expression profiles at 
      the single-cell level, we identified four clusters of malignant B cells with 
      distinct transcriptional signatures, showing high intra-tumoral heterogeneity. 
      Among them, heterogeneity was reflected in activating several key pathways, human 
      leukocyte antigen (HLA)-related molecules' expression, and key oncogenes, which 
      may lead to multi-drug resistance. In addition, FOXP3+ regulatory CD4+ T cells 
      and exhausted cytotoxic CD8+ T cells were identified, accounted for a significant 
      proportion, and showed highly immunosuppressive properties. Finally, cell 
      communication analysis indicated complex interactions between malignant B cells 
      and T cells. In conclusion, this case report demonstrates the value of 
      single-cell RNA sequencing for visualizing the tumor microenvironment and 
      identifying potential therapeutic targets in a patient with treatment-refractory 
      DLBCL. The combination of NGS and single-cell RNA sequencing may facilitate 
      clinical decision-making and drug selection in challenging DLBCL cases.
CI  - Copyright (c) 2024 Zhao, Li, Li, Liu, Liu, Zhu and Zhang.
FAU - Zhao, Kewei
AU  - Zhao K
AD  - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of 
      Science and Technology, Wuhan, China.
FAU - Li, Qiuhui
AU  - Li Q
AD  - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of 
      Science and Technology, Wuhan, China.
FAU - Li, Pengye
AU  - Li P
AD  - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of 
      Science and Technology, Wuhan, China.
FAU - Liu, Tao
AU  - Liu T
AD  - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of 
      Science and Technology, Wuhan, China.
FAU - Liu, Xinxiu
AU  - Liu X
AD  - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of 
      Science and Technology, Wuhan, China.
FAU - Zhu, Fang
AU  - Zhu F
AD  - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of 
      Science and Technology, Wuhan, China.
FAU - Zhang, Liling
AU  - Zhang L
AD  - Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of 
      Science and Technology, Wuhan, China.
LA  - eng
PT  - Case Reports
DEP - 20240312
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
SB  - IM
MH  - Humans
MH  - Transcriptome
MH  - Neoplasm Recurrence, Local/drug therapy
MH  - *Lymphoma, Large B-Cell, Diffuse/pathology
MH  - *Lymphoma, Non-Hodgkin/drug therapy
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Tumor Microenvironment
PMC - PMC10963401
OTO - NOTNLM
OT  - diffuse large B-cell lymphoma
OT  - single-cell RNA sequencing
OT  - treatment resistance
OT  - tumor heterogeneity
OT  - tumor immune microenvironment
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2024/03/27 06:44
MHDA- 2024/03/28 06:44
PMCR- 2024/01/01
CRDT- 2024/03/27 03:59
PHST- 2023/09/27 00:00 [received]
PHST- 2024/02/21 00:00 [accepted]
PHST- 2024/03/28 06:44 [medline]
PHST- 2024/03/27 06:44 [pubmed]
PHST- 2024/03/27 03:59 [entrez]
PHST- 2024/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2024.1303310 [doi]
PST - epublish
SO  - Front Immunol. 2024 Mar 12;15:1303310. doi: 10.3389/fimmu.2024.1303310. 
      eCollection 2024.